Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 15/20 | 0.66 |
| ▸ | IGF1R | P08069 | 10/20 | 0.66 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.66 |
| ▸ | PTK2B | Q14289 | 4/20 | 0.66 |
| ▸ | INSR | P06213 | 9/20 | 0.65 |
| ▸ | EGFR | P00533 | 5/20 | 0.65 |
| ▸ | PLK4 | O00444 | 3/20 | 0.65 |
| ▸ | LCK | P06239 | 3/20 | 0.65 |
| ▸ | FYN | P06241 | 3/20 | 0.65 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.65 |
| ▸ | FLT3 | P36888 | 3/20 | 0.65 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.65 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.65 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.65 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.65 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.65 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.65 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100115 | 0.94 | ALK (0.63) | ALKIGF1RPTK2PTK2BINSR | |
| SCHEMBL4089503 | 0.93 | ALK (0.70) | ALKIGF1RPTK2PTK2BINSR | |
| SCHEMBL4103561 | 0.93 | ULK1 (0.67) | ALKIGF1RPTK2PTK2BINSR | |
| SCHEMBL4094604 | 0.92 | ALK (0.72) | ALKIGF1RPTK2PTK2BINSR | |
| SCHEMBL4089370 | 0.89 | ALK (0.68) | ALKIGF1RPTK2PTK2BINSR | |
| SCHEMBL4099223 | 0.89 | ALK (0.77) | ALKIGF1RPTK2PTK2BINSR | |
| SCHEMBL4093702 | 0.89 | ALK (0.70) | ALKIGF1RPTK2PTK2BINSR | |
| SCHEMBL4095865 | 0.86 | ULK1 (0.74) | ALKIGF1RPTK2PTK2BINSR | |
| SCHEMBL2829179 | 0.86 | ALK (0.83) | ALKIGF1RPTK2PTK2BINSR | |
| SCHEMBL5361563 | 0.85 | ZAP70 (0.61) | ALKIGF1RPTK2PTK2BINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | claimed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | claimed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | claimed |
| US-20090131436-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131436-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | ALK 2060/4885IGF1R 4608/4885PTK2 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.